Close Menu

NEW YORK (GenomeWeb) – Veracyte said today that Medicare contractor Palmetto GBA has confirmed its local coverage determination for the Percepta Bronchial Genomic Classifier, a molecular test that identifies and screens patients with lung nodules who are at low risk of cancer following an inconclusive bronchoscopy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.